Company Overview - Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [3] - The company utilizes its Genome5000™ program to study nearly 5,000 genes, identifying over 100 protein targets with significant therapeutic potential across various diseases [3] - Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in areas such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [3] Upcoming Events - Company management will participate in a fireside chat at Citi's Biopharma Back to School Conference on September 3 at 1:45 p.m. ET [1] - The company will also present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 3:00 p.m. ET [1] - Live events and replays of the presentations will be accessible via the company's Events page on its website [2]

Group 1 - Lexicon Pharmaceuticals has regained compliance with Nasdaq Listing Rule 5550(a)(2) as its common stock has maintained a closing bid price of $1.00 or greater for ten consecutive business days [1] - The update regarding compliance was previously disclosed in the Company's Current Report on Form 8-K filed on July 28, 2025 [1] Group 2 - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [2] - The company utilizes its Genome5000™ program to study nearly 5,000 genes, identifying over 100 protein targets with significant therapeutic potential across various diseases [2] - Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in areas such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [2]

Company Announcement - Lexicon Pharmaceuticals, Inc. will release its second quarter 2025 financial results on August 6, 2025, prior to market open [1] - Management will conduct a conference call and live webcast at 8:30 a.m. ET on the same day to discuss the financial results and provide a business update [1] Conference Call Details - Participants can access the conference call live via webcast on the Company's website [2] - Those wishing to ask questions may register to receive dial-in numbers and a unique pin to join the call [2] - An archived version of the webcast will be available on the Lexicon website [2] Company Overview - Lexicon is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [3] - The Genome5000™ program has enabled Lexicon scientists to study nearly 5,000 genes, identifying over 100 protein targets with significant therapeutic potential [3] - The company has advanced multiple medicines to market and has a pipeline of promising drug candidates in various therapeutic areas including heart failure, neuropathic pain, obesity, cardiology, and diabetes [3]

Group 1 - Lexicon Pharmaceuticals will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference on May 20, 2025, at 9:30 a.m. ET [1] - The event will be accessible live and as a replay on the company's website [1] Group 2 - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [2] - The company has developed a unique genomics target discovery platform called Genome5000™, studying nearly 5,000 genes and identifying over 100 protein targets with therapeutic potential [2] - Lexicon has advanced multiple medicines to market and has a pipeline of drug candidates in various stages of development for conditions such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [2]

Company Announcement - Lexicon Pharmaceuticals, Inc. will release its first quarter 2025 financial results on May 13, 2025, after market close [1] - A conference call and live webcast will be held on the same day at 5:00 p.m. ET to discuss the financial results and provide a business update [1] Conference Call Access - Participants can access the conference call live via the company's website [2] - Registration is required for participants who wish to ask questions, providing them with dial-in numbers and a unique pin [2] - An archived version of the webcast will be available on the Lexicon website [2] Company Overview - Lexicon is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [3] - The Genome5000™ program has enabled Lexicon to study nearly 5,000 genes, identifying over 100 protein targets with significant therapeutic potential [3] - The company has advanced multiple medicines to market and has a pipeline of drug candidates in various stages of development for conditions such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [3]

Group 1 - Lexicon Pharmaceuticals will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 on March 12 at 10:00 a.m. ET [1] - The event will be accessible live and as a replay on the company's website [1] Group 2 - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives [2] - The company utilizes the Genome5000™ program to study nearly 5,000 genes, identifying over 100 protein targets with significant therapeutic potential [2] - Lexicon has advanced multiple medicines to market and has a pipeline of drug candidates in various stages of development for conditions such as heart failure, neuropathic pain, obesity, cardiology, and diabetes [2]